4169.TW TCM Biotech International Corp.
- Market cap
- TWD 7.57B
- P/E
- -
- P/B
- 3.87x
- ROE
- -3.6%
- Dividend yield
- 0.27%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4169.TW undervalued?
Graham numberThe Graham number of TCM Biotech International Corp. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
TCM Biotech International Corp. fundamental analysis
No fundamental analysis for TCM Biotech International Corp. yet.
TCM Biotech International Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About TCM Biotech International Corp.
TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for liver diseases. The company offers medical devices, such as therapy for osteoarthritis, intra-articular implant of hyaluronic acid, automated blood cell separator, absorbable adhesion barrier material, prosthetic and orthotic accessory, and pellefeel mask pressure relief pad; and pharmaceuticals, including iron supplement, therapeutic agent for urinary system, expectorant…
Full company profileTCM Biotech International Corp. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
TCM Biotech International Corp. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 506M | 541M | 540M | 569M | 737M | 702M | 802M | 970M | 667M | 685M | 708M |
| Gross Profit | 206M | 238M | 260M | 273M | 369M | 359M | 448M | 480M | 327M | 297M | 307M |
| Operating Income | 29.6M | 29.4M | 31.5M | 13.7M | 37.1M | 2.13M | 25.3M | 22.3M | 10.0M | 18.7M | -76.7M |
| EBITDA | 37.0M | 38.8M | 44.1M | 29.6M | 53.2M | 22.3M | 45.5M | 46.7M | 50.5M | 42.2M | -55.3M |
| Net Income | 32.9M | 18.9M | 24.8M | 6.51M | 25.5M | 1.87M | 18.3M | 18.6M | 21.0M | 19.2M | -69.6M |
| EPS | 0.64 | 0.37 | 0.49 | 0.13 | 0.51 | 0.04 | 0.37 | 0.35 | 0.36 | 0.32 | -1.05 |
| Balance Sheet | |||||||||||
| Total Assets | 639M | 754M | 809M | 765M | 772M | 820M | 863M | 1.32B | 1.18B | 1.20B | 2.10B |
| Total Liabilities | 99.1M | 226M | 273M | 254M | 255M | 302M | 326M | 268M | 123M | 149M | 150M |
| Shareholders' Equity | 540M | 528M | 535M | 511M | 517M | 518M | 537M | 1.06B | 1.06B | 1.06B | 1.95B |
| Cash & Short-term Investments | 207M | 107M | 85.6M | 121M | 34.3M | 58.3M | 89.9M | 504M | 533M | 545M | 1.20B |
| Total Debt | 19.4M | 138M | 165M | 152M | 139M | 166M | 171M | 123M | 51.0M | 42.9M | 24.9M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -71.3M | 62.5M | 26.6M | -20.9M | 74.9M | 15.3M | 52.2M | -37.5M | 167M | 39.0M | -98.4M |
| Capital Expenditure | 1.98M | 251M | 57.9M | 2.28M | 21.7M | 7.71M | 5.29M | 4.91M | 8.36M | 2.49M | 7.50M |
| Free Cash Flow | -73.3M | -189M | -31.3M | -23.2M | 53.2M | 7.61M | 47.0M | -42.4M | 159M | 36.5M | -106M |
| Ratios | |||||||||||
| ROE | 6.1% | 3.6% | 4.6% | 1.3% | 4.9% | 0.4% | 3.4% | 1.8% | 2.0% | 1.8% | -3.6% |
| ROA | 5.1% | 2.5% | 3.1% | 0.9% | 3.3% | 0.2% | 2.1% | 1.4% | 1.8% | 1.6% | -3.3% |
| Net Profit Margin | 6.5% | 3.5% | 4.6% | 1.1% | 3.5% | 0.3% | 2.3% | 1.9% | 3.2% | 2.8% | -9.8% |
| Debt to Equity | 0.04x | 0.26x | 0.31x | 0.30x | 0.27x | 0.32x | 0.32x | 0.12x | 0.05x | 0.04x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
TCM Biotech International Corp. dividends
- Dividend yield
- 0.27%
- Forward dividend
- 0.32 TWD
- Payout ratio
- 107.8%
- Ex-dividend date
- Jul 20, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 20.7M | 0.35 | 107.8% |
| 2024 | TWD 16.8M | 0.28 | 80.1% |
| 2023 | TWD 1.62M | 0.03 | 8.7% |
| 2022 | - | - | - |
| 2021 | 16.9M | 0.33 | 903.2% |
| 2020 | 18.8M | 0.37 | 73.6% |
| 2019 | 17.9M | 0.35 | 274.2% |
| 2018 | 17.1M | 0.34 | 69.1% |
| 2017 | 30.0M | 0.58 | 158.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1030.6:1000 on Jul 20, 2023.
Who owns TCM Biotech International Corp.
- Insiders 40.72%
- Institutions 0.04%
- Public & others 59.24%
- Shares outstanding 66.1M
- Free float 43.8M
TCM Biotech International Corp. company profile
- Company name
- TCM Biotech International Corp.
- Ticker
- 4169.TW
- Exchange
- Taiwan Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 24Floor-8, No.97, Section 1, Taipei, Taiwan, 221416
- Phone
- 886 2 2697 2628
- Website
- tcmbio.com
About TCM Biotech International Corp.
TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for liver diseases. The company offers medical devices, such as therapy for osteoarthritis, intra-articular implant of hyaluronic acid, automated blood cell separator, absorbable adhesion barrier material, prosthetic and orthotic accessory, and pellefeel mask pressure relief pad; and pharmaceuticals, including iron supplement, therapeutic agent for urinary system, expectorant/mucolytic agent, anticancer drug, antihypertensive drug, and antidiabetic. It also provides medical detection platform for breast cancer recurrent risk detection and postoperative detection platform for liver cancer, as well as philips non-invasive positive pressure ventilation and accessories. TCM Biotech International Corp. was founded in 1998 and is headquartered in New Taipei City, Taiwan.
TCM Biotech International Corp. management
6- Dr. Ya-Chun WangGM & Director
- Xiu Ming WeiFinancial Manager
- Shu Ya YangAccounting Manager
- Bing Rong DuAdministration Department Manager
- Prof. Pei-Jer Chen M.D., MBBS, Ph.D.Chief Advisor
- Zhen Yao ChenVP of R&D and Chief Research and Development Officer